Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Edesa Biotech, Inc. EDSA

13 fiscal years on record · USD · FY2025 reported · SEC filings only
$-7.2M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

·
Revenue, FY2025 · full 13-year series below
Revenue $M Net income $M
FY2021 · Revenue 0.0 · Net income -13.3
-10M-20M
20122015201820222025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2020 · Operating -1946.7% · Net ·
-1000%-2000%
201220182025
ROE
FY2025 · ROE -99.6%
-200%-400%-600%
201220182025
Three returns, three denominators.

Each USD of equity lost 100 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2023 · FCF -6.6
-5M-10M
201220182025

Total assetsUSD 13.5M
EquityUSD 12.5M
CashUSD 10.8M
Current ratio10.67×

Equity funds 92% of total assets.

The 13-year record

13 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
EDSA, 13-year financial record
Metric 2025202420232022202120202018201720162015201420132012
Revenue $B◌◌◌◌0.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌
EBITDA $B−0.0−0.0−0.07.08.39.6−0.0−0.0−0.0−0.0−0.0◌◌
Income tax $B0.00.00.00.00.00.00.00.00.00.00.00.00.0
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B◌◌−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $◌◌◌◌−1.10−0.74−1.76−3.44−0.57−0.36−1.11−2.81−0.13
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————————
ROE %−99.6−136.7−101.9−156.3−135.5−96.0−53.9−51.0−49.5−36.2——−612.9
Shares out B0.010.000.000.020.010.010.010.010.010.010.080.06◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 49 reconciliationsAUDITED

Reconciled in 13 of the 13 fiscal years we could check. 12 checks were skipped: the balance sheet is not tagged before 2013. Five checks were skipped: EPS is not tagged before 2012. Five checks were skipped: revenue is not tagged before 2012.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code A1
Fiscal year endsSeptember 30
SEC categorysmaller reporting company
Data on record since2012

Share this section

Download image